About Abelacimab Abelacimab is a novel, investigational, highly selective, fully human monoclonal antibody that binds tightly to Factor XI to block its activation and prevent the generation of the ...
Novartis UK announced the Medicines and Healthcare products Regulatory Agency (MHRA) has authorised ribociclib for adjuvant ...
The approval – which applies to England, Scotland and Wales as Northern Ireland remains under EMA jurisdiction – gives Novartis its second radioligand therapy in Europe after Lutathera (177Lu ...
Joint research activities will be carried out at Novartis’ sites in Basel, Switzerland, and Dublin, Ireland, as well as at the Microsoft Research Lab in Cambridge, UK.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback